Efficacy

Wezlana (ustekinumab-auub) for Psoriasis

Wezlana, with the active ingredient ustekinumab-auub, is a biologic medication approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Clinical trials have demonstrated that Wezlana is effective in reducing the extent and severity of psoriatic plaques. The efficacy of Wezlana is measured by the Psoriasis Area and Severity Index (PASI) score, which assesses the overall severity and coverage of psoriatic lesions. In pivotal trials, a significant number of patients treated with Wezlana achieved a PASI 75 response, which indicates a 75% reduction in the PASI score from baseline, often considered a marker of significant clinical improvement.

Furthermore, Wezlana has been shown to maintain its efficacy over the long term, with many patients sustaining their PASI 75 response with continued treatment. The medication works by targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), two cytokines that are known to play a key role in the inflammatory processes associated with psoriasis. By inhibiting these cytokines, Wezlana helps to reduce the inflammation and subsequent skin cell turnover that leads to the development of psoriatic plaques.

Simlandi (adalimumab-ryvk) for Psoriasis

Simlandi, containing the active ingredient adalimumab-ryvk, is another biologic therapy approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Simlandi has been shown to be highly effective in clinical studies, with a significant proportion of patients achieving clear or almost clear skin as measured by the PASI score. The efficacy of Simlandi is also evaluated using the PASI 75 response, and clinical trials have reported that a majority of patients reach this level of response within 16 weeks of treatment initiation.

Simlandi works by targeting tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine that is elevated in psoriatic lesions. By neutralizing TNF-alpha, Simlandi helps to reduce the inflammation, scaling, and thickness of psoriatic plaques. The sustained efficacy of Simlandi has been observed in long-term studies, with patients maintaining their PASI 75 response with ongoing treatment. Additionally, Simlandi has been associated with improvements in quality of life and other patient-reported outcomes, highlighting its effectiveness in managing the symptoms and impact of psoriasis.